ONC: BeiGene Ltd. Narx/daromad koeffitsiyenti

BeiGene Ltd. (ONC) kompaniyasining korporativ logotipi

BeiGene Ltd strategik sherikliklar va molekulalarni litsenziyalash orqali onkologiyaning ilg'or davolash usullarini ishlab chiqmoqda. P/S koeffitsiyentining tarixiy o'rtacha qiymatidan chetlashishi bozor baholashini ko'rsatadi, bunda joriy daraja 6.60 ni tashkil etadi. Klinik sinovlarga global yondashuv hamyonbop dori vositalarini chiqarishni tezlashtiradi, biroq hukumatning qat'iy narx nazorati va ulkan R&D xarajatlari biznes marjasi uchun jiddiy qiyinchiliklar tug'diradi.

BeiGene Corp (ONC) P/S multiplikatori: 04.07.2022 - 13.11.2026 davri uchun

BeiGene Corp (ONC) kompaniyasining tahliliy kesimlari

- joriy kotirovkalar va o'rtacha qiymat prognozi:
Birja narxi beigene.com|ONC - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi haqida ma'lumot:
Bozor kapitallashuvi BeiGene Corp|ONC - Korxona qiymati
- kompaniyaning balans qiymati tafsilotlari:
Yagona aksiya balans qiymati BeiGene|ONC - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga koeffitsiyenti beigene.com|ONC - Kompaniyaning jami aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning xususiy kapitalga nisbati BeiGene Ltd|ONC - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati BeiGene Oncology|ONC - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati BeiGene Corp|ONC - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzi BeiGene|Oraliq likvidlik koeffitsiyenti beigene.com
- foyda va bozor multiplikatorlari tafsilotlari:
ONC - Sof foyda|Sof foyda prognozi BeiGene Ltd|ONC - Narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati BeiGene Ltd.|ONC - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati BeiGene Corp|ONC - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda BeiGene|ONC - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi beigene.com|ONC - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi BeiGene Ltd
- emitentning tushumi va sotuvlari tafsilotlari:
ONC - Kompaniya daromadi|Kompaniya daromadi prognozi beigene.com|ONC - P/S multiplikatori|Forvard narx/daromad multiplikatori BeiGene Corp
Kompaniyaning jamlanma tahliliyoti:beigene.com, ONC
BeiGene tomonidan chiqariladigan mahsulotlar

BeiGene Ltd (ONC) kompaniyasidagi samarali xalqaro logistika va ishlab chiqarish diversifikatsiyasi daromadning barqaror o'sishini ta'minlaydi, bu esa savdolarga asoslangan biznes baholashni barqarorlikning asosiy ko'rsatkichiga aylantiradi. P/S koeffitsiyentini tahlil qilish orqali investor bozor kapitalizatsiyasining savdo hajmi nisbatini ko'rishi mumkin, bu esa aktiv uchun haddan tashqari to'lov darajasini aniqlashga va kompaniya operatsiyalarining kengayishi bo'yicha bozor kutuvlarini baholashga yordam beradi.

BeiGene Ltd raqobatchilari

HALO - Sotuvga nisbatan narx|P/S multiplikatori RVMD (Revolution Medicines, Inc.)|Narx/daromad koeffitsiyenti Ascentage Pharma Group International (AAPG)|CG Oncology Corp - P/S multiplikatori|Narx/daromad multiplikatori UroGen Pharma Corp (URGN)|BCAX: P/S multiplikatori|Sotuvga nisbatan narx personalis.com (PSNL)|Narxning daromadga nisbati Erasca|Kapitalizatsiya va daromad nisbati DCTH (Delcath Systems Inc)|P/S multiplikatori YMAB|AURA - Sotuvga nisbatan narx|Candel Therapeutics, Inc. - Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati ARAY|SLS - Narxning daromadga nisbati|ACTU: Narxning daromadga nisbati|CTOR (Citius Oncology, Inc) - Kapitalizatsiyaning daromadga nisbati|HURA: Kapitalizatsiyaning sotish hajmiga nisbati|TARA (Protara Therapeutics) - P/S multiplikatori|Kapitalizatsiya va daromad nisbati FATE (fatetherapeutics.com)|Narxning daromadga nisbati Aadi Bioscience Inc (WHWK)|TCRX - Sotuvga nisbatan narx|Narxning daromadga nisbati Champions Oncology, Inc. CSBR|XBIT: Kapitalizatsiya va daromad nisbati|CEL-SCI Corp - P/S multiplikatori|ostherapies.com (OSTX) - Kapitalizatsiyaning daromadga nisbati|RADX: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Artiva Biotherapeutics|ANL (Adlai Nortye Ltd) - P/S multiplikatori|P/S multiplikatori Veru Corporation|Narxning daromadga nisbati Tempest Therapeutics (TPST)|xiliotx.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori RENB (Renovaro)|MURA - Kapitalizatsiyaning daromadga nisbati|Kairos Pharma Inc - P/S multiplikatori|Sotuvga nisbatan narx OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Narxning daromadga nisbati|Curis - Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati APLM|THAR: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori ADVB|Kapitalizatsiyaning daromadga nisbati Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Kapitalizatsiyaning daromadga nisbati|P/S multiplikatori sunshinebiopharma.com SBFM|XBIO - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati SLRX (Salarius Pharmaceuticals Inc)|PPBT: P/S multiplikatori|Sotuvga nisbatan narx American Oncology Network, Inc. (AONC)|BGNE (BeiGene, Ltd.) - P/S multiplikatori|Narxning daromadga nisbati CKPT|P/S multiplikatori ELEV|ICAD - Sotuvga nisbatan narx|P/S multiplikatori IKNA (Ikena Oncology)|Narx/daromad koeffitsiyenti Notable Labs Corp (NTBL)|Viracta - P/S multiplikatori|Narx/daromad multiplikatori morphosys.com (MOR)|NAYA: P/S multiplikatori|Sotuvga nisbatan narx Ascentage Pharma Group International (AAPGV)